Abstract
The treatment of diabetic wounds faces enormous challenges due to complex wound environments, such as infected biofilms, excessive inflammation, and impaired angiogenesis. The critical role of the microenvironment in the chronic diabetic wounds has not been addressed for therapeutic development. Herein, we develop a microneedle (MN) bandage functionalized with dopamine-coated hybrid nanoparticles containing selenium and chlorin e6 (SeC@PA), which is capable of the dual-directional regulation of reactive species (RS) generation, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), in response to the wound microenvironment. The SeC@PA MN bandage can disrupt barriers in wound coverings for efficient SeC@PA delivery. SeC@PA not only depletes endogenous glutathione (GSH) to enhance the anti-biofilm effect of RS, but also degrades GSH in biofilms through cascade reactions to generate more lethal RS for biofilm eradication. SeC@PA acts as an RS scavenger in wound beds with low GSH levels, exerting an anti-inflammatory effect. SeC@PA also promotes the M2-phenotype polarization of macrophages, accelerating wound healing. This self-enhanced, catabolic and dynamic therapy, activated by the wound microenvironment, provides an approach for treating chronic wounds.
Subject terms: Drug delivery, Biomedical materials, Nanoparticles
The treatment of diabetic wounds tends to be hindered by complex wound environments, and the critical role of the microenvironment in the chronic diabetic wounds has not been explored for therapeutic development. Here, the authors develop a wound microenvironment-responsive microneedle bandage to achieve self-enhanced, catabolic and dynamic therapy of chronic wounds.
Introduction
Chronic wounds are a common complication of diabetes that affect ~25% of patients with diabetes1,2. The annual costs for treating chronic wounds and scars exceed $5 billion, imposing a huge financial burden on patients and the healthcare system3. The healing process of diabetic wounds is hindered by biofilms infections, persistent inflammation, and impaired angiogenesis4–6. Currently, several therapeutic strategies are available for managing diabetic wounds, including aggressive debridement, surgical angiogenesis, antibacterial therapy, and bioengineered alternative tissue products7,8. However, most of these strategies are restricted by the complex pathogenesis of chronic wounds and are not completely effective for the treatment of diabetic wounds. Therefore, there is a need for the development of versatile therapeutic strategies encompassing antibacterial, anti-inflammatory, and pro-angiogenesis effects to address the treatment of diabetic wounds.
Chronic wounds, including diabetic wounds, are frequently infected with biofilms9,10. Bacteria are protected by extracellular polymeric substances (EPS) of the biofilms that form a strong barrier against antibiotics and immune cells11,12. Because of being packed in EPS, these biofilms exhibit specific microenvironments in wound beds, such as low pH and high levels of glutathione (GSH)13,14. Therefore, exploiting the special characters of the biofilms microenvironment is a promising strategy to prevent biofilms infections. Photodynamic therapy (PDT), a minimally invasive procedure that does not involve issues of drug resistance, has received significant attention as an antibacterial approach15–17. There are challenges associated with the use of PDT to effectively treat biofilms infections, as the ROS generated by photosensitizers (PS) can be depleted by the high levels of GSH in biofilms18. To address these issues, most studies focus on the depletion of endogenous GSH by mediators such as nitric oxide (NO)12 or Cu2+.19 However, the strategy of exploiting high GSH level in biofilms to enhance PDT has been barely reported. Previous studies have shown that selenite (SeO32−) could target high GSH levels in tumor cells to produce ROS, including O2•− and •OH20–22. In contrast, ROS production, which is lethal to cells, is not triggered in normal cells with low GSH levels, thereby protecting cells from apoptosis22. Based on this inspiration, we propose a strategy to effectively amplify PDT by depleting endogenous GSH, and generate active molecules that are more lethal to biofilms by utilizing endogenous GSH, thus facilitating the eradication of biofilms.
Another point of concern is that ROS is a double-edged sword23. Wound beds covered by biofilms are excessively inflammatory, and oxidative stress in wounds can be aggravated by the ROS produced during PDT to destroy biofilms, leading to impaired wound healing24. Therefore, the prompt elimination of ROS during PDT is crucial to prevent further exacerbation of wound inflammation, as well as enhance the antioxidative capacity of the wound beds for providing an anti-inflammatory effect from the outside to the inside. Moreover, an important factor affecting the efficacy of therapeutics is their point of delivery. The importance of the role of the delivery point in promoting wound healing has been well studied9. Chronic wounds are typically covered with inflammatory exudates and biofilms25, which constitute a physicochemical barrier hindering the penetration of topical therapeutic agents into the underlying live tissues. Thus, when drugs are applied topically, their local bioavailability is reduced, as expected. A delivery system that can disrupt the physiochemical barriers created by inflammatory exudates and biofilms, shorten the travel distance of therapeutics by directly delivering them to wound tissue can improve drug efficacy.
In this work, we develop a multifunctional microneedle (MN) bandage for diabetic wound treatment. As shown in Fig. 1a, dopamine-coated hybrid nanoparticles (SeC@PA) containing selenium (Se) and chlorin e6 (Ce6) are firstly prepared, and then modified with L-arginine (LA) on the surface. The MN bandage is loaded with SeC@PA to obtain SeC@PA MN. When the SeC@PA MN is applied to diabetic wounds, the physiochemical barriers are broken, and SeC@PA are effectively delivered to the biofilms and wound live tissue (Fig. 1b). We hypothesize that after delivery into the biofilm-infected sites, SeC@PA can not only deplete GSH and generate reactive nitrogen species (RNS) to enhance the anti-biofilms effect of PDT, but also utilize the high levels of GSH in biofilms to generate hydroxyl radical (•OH) through a series of catalytic cascade reactions (Fig. 1c). Conversely, after delivery into the highly inflammatory wound tissue, SeC@PA exhibits potent antioxidant effects by rapidly scavenging RS and enhancing glutathione peroxidase (GPX) activity (Fig. 1d). Moreover, SeC@PA can effectively promote macrophage polarization toward the M2-phenotype, thereby facilitating wound healing (Fig. 1e). The bidirectional regulation of RS by SeC@PA through different GSH levels is demonstrated both in vitro and in vivo. The therapeutic efficacy of SeC@PA MN is studied in a mouse model of diabetic wounds. Our study highlights a self-augmented, catabolic, and dynamic therapy to effectively manage chronic diabetic wounds.
Results
Preparation and characterization of SeC@PA and SeC@PA MN bandage
In this study, Se was first prepared following an established method26,27. Transmission electron microscopy (TEM) images indicated that Se particles were uniform with an average diameter of 38.42 ± 0.85 nm (Supplementary Fig. 1a, d). Dopamine (DA) was used to coat the surface of Se and encapsulate the photosensitizer (Ce6) to obtain SeC@P. LA was adsorbed on the surface of SeC@P by electrostatic interaction to form SeC@PA. The characterization results are shown in Fig. 2. Product morphologies were observed using TEM. SeC@P exhibited a spheroid morphology (Supplementary Fig. 1e) with good dispersity similar to that of Se@PA (Fig. 2a). The hydrodynamic diameters of SeC@P and SeC@PA were 90.00 ± 1.82 nm and 108.47 ± 1.01 nm (Supplementary Fig. 1b, c), respectively. The zeta potentials indicated that SeC@P had a negative charge and SeC@PA had a positive charge (Supplementary Fig. 1f), suggesting that the positively charged LA was successfully introduced on the surface. The successful assembly of SeC@PA was also validated using the scanning electron microscopy (SEM) energy dispersive spectrometer (EDS) (Supplementary Fig. 2) and X-ray photoelectron spectroscopy (XPS) (Supplementary Fig. 3). The results revealed that SeC@PA was composed of not only the basic elements C, O, and N, but also Se. The loading efficiency of Se, Ce6, and LA in SeC@PA was calculated as 23.23 ± 4.11%, 8.40 ± 4.38%, and 12.60 ± 3.79%, respectively (Supplementary Table 1).
It was expected that the delivery of SeC@PA to biofilms would result in the rapid degradation of the PDA layer, leading to the release of Ce6 and Se. This release would trigger a cascade reaction, generating an RS storm to eradicate the biofilms. Therefore, we studied the release behavior of Ce6 and Se from SeC@PA under different pH conditions. The release of Ce6 from SeC@PA was accelerated in a weakly acidic environment (pH = 5.5) (Supplementary Fig. 4) and Se was also successfully released in pH = 5.5 condition (Supplementary Fig. 5). Since the biofilm microenvironment is weakly acidic28,29, Se and Ce6 were effectively released to the action point when SeC@PA was delivered to the biofilms. Next, we investigated whether singlet oxygen (1O2) produced by Ce6 could oxidize LA adsorbed on the surface to produce NO for GSH depletion and RNS formation, thereby amplifying the RS anti-biofilm effect. The studies showed that NO was successfully detected under irradiation (Fig. 2b, c), which positively correlated with irradiation intensity and SeC@PA concentration. We also examined that 1O2 produced by Ce6 during irradiation could oxidize the Se released from SeC@PA to Se4+ in the first step of the cascade. High-resolution XPS revealed that Se3d from SeC@PA with irradiation (SeC@PA(+)) consisted of Se0 (54.73 eV and 55.53 eV) and Se4+ (58.20 eV and 59.06 eV) (Fig. 2f). In contrast, Se and SeC@PA without irradiation only contained Se0 (54.73 eV and 55.53 eV) (Supplementary Fig. 6), indicating that the Se released from SeC@PA could be oxidized to Se4+ under irradiation.
To verify the ability of SeC@PA to bidirectionally regulate RS at different GSH levels in vitro, the fluorescent probe 2,7-dichlorofluorescein diacetate (DCF-DA) was used to evaluate RS generation. As shown in Fig. 2d, abundant RS was produced by C@PA under irradiation (C@PA(+)) in PBS solution (pH = 5.5) without GSH. At the same time, RS generated by SeC@PA(+) was significantly reduced, proving that Se could eliminate RS in the absence of GSH. Nevertheless, when C@PA(+) was co-incubated with 8 mM GSH (high GSH levels in biofilms), RS levels were dramatically decreased due to the depletion by GSH. Surprisingly, unlike C@PA(+), SeC@PA(+) exhibited the highest RS levels in 8 mM GSH solution, which was attributed to Se producing RS with more oxidative activity by decomposing GSH. In vitro experiment results demonstrated that SeC@PA(+) could more quickly deplete GSH during irradiation compared with C@PA(+) (Fig. 2i). Subsequently, we explored the impact of varying concentrations of GSH on the RS generated by SeC@PA (+) and C@PA (+). As exhibited in Fig. 2e, the intensity of RS in the C@PA(+) group was observed to decrease with increasing GSH concentration, which was attributed to the scavenging effect of GSH on the RS. In contrast, SeC@PA(+) played a role in scavenging RS at low GSH concentrations (≤0.4 mM), while enhancing RS intensity at high concentrations (≥ 0.8 mM). A turning point was clearly observed, which indicated that SeC@PA successfully achieved bidirectional regulation of RS. When a low-level GSH (2 μm), for simulating the GSH concentration in healthy tissue, was introduced into the system, similar results were obtained as compared with that without GSH, where SeC@PA(+) mainly acted as a RS scavenger (Supplementary Fig. 7). Electron paramagnetic resonance (EPR) (Fig. 2g, h) and methylene blue (MB) (Supplementary Fig. 8) degradation were used to determine •OH production. The results showed that SeC@PA(+) could produce active •OH only when GSH levels were high. These results suggested that at high GSH levels, SeC@PA(+) participated in GSH degradation and led to higher RS levels, whereas RS-scavenging ability was exhibited at low GSH levels, thereby achieving bidirectional RS regulation.
We successfully prepared the SeC@PA-loaded MN bandage (Fig. 2j). The SeC@PA MN bandage exhibited rapid dissolution performance in PBS (Supplementary Fig. 9), indicating that the application time of the SeC@PA MN bandage was short. To assess the delivery efficiency of SeC@PA, we assembled an in vitro model mimicking the wound barrier. The in vitro model consisted of biofilms formed by Escherichia coli (EC) expressing the green fluorescent protein (GFP) in an agarose gel. A rhodamine-loaded SeR@PA MN bandage was applied on the top of the mold to simulate topical drug delivery. At the same time, SeR@PA nanoparticles (NPs) were added to the top of the mold for comparison. The results (Fig. 2k) demonstrated the remarkable capability of the MN bandage to penetrate barriers and directly deliver SeR@PA to the desired target region. In contrast, SeR@PA NPs alone exhibited limited penetration, primarily confined to the surface of the barrier, thereby impeding its ability to reach the deeper target regions. Collectively, these results suggested that the MN bandages could overcome the obstacles of local drug delivery in chronic wounds, delivering the drug directly to the site of action for therapeutic effect.
Anti-biofilm property of SeC@PA
For anti-biofilm evaluation, Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) were used as the representative strains as they are the most common species isolated from chronic wound biofilms30. The antibacterial activity and cell viability were first investigated with different concentrations of SeC@PA(+). As shown in Supplementary Fig. 10, the antibacterial activity was enhanced with an increased concentration of SeC@PA(+) and also accompanied by stronger cytotoxicity. To balance the antibacterial activity and cytotoxicity, we selected a concentration of SeC@PA containing 20 μg/mL of Se, 7.2 μg/mL of Ce6, and 10.8 μg/mL of LA for follow-up studies. Next, we explored the bactericidal effects of different agents on SA and PA. Both C@PA(+) and SeC@PA(+) had strong antibacterial effects (Supplementary Fig. 11), demonstrating the antimicrobial potential by targeting RS.
To elucidate the “RS storm” strategy, we investigated the anti-biofilm contribution of each kind of RS (1O2, RNS, and •OH) produced in SeC@PA(+) by RS superposition method, which was specifically described in the method section. 1O2 was generated in C@P + 8 mM GSH group, C@PA + 8 mM GSH group, and SeC@PA + 8 mM GSH group, RNS was produced in C@PA + 8 mM GSH group, and SeC@PA + 8 mM GSH group, while •OH was only generated in SeC@PA + 8 mM GSH group, and the intensity of each RS had no obvious difference (Supplementary Fig. 12 and Supplementary Fig. 13a). Next, we explored the production of RS by different groups in the biofilms. As presented in Supplementary Fig. 13b, d, DCF fluorescence intensity in SA biofilm was SeC@PA(+) group > C@PA(+) group > C@P(+) group, due to the addition of RS. Simultaneously, the anti-biofilm effects of different groups were investigated. The live/dead biofilm images, crystal violet staining, and bactericidal results are shown in Supplementary Fig. 13c, e, f, respectively. The results showed that the biofilm in the C@P(+) group remained relatively intact and only exhibited weak anti-biofilm effects. In contrast, the anti-biofilm effect was obviously enhanced in the C@PA(+) group with compromised biofilm integrity, which should be due to the reason that the addition of RNS resulted in a stronger anti-biofilm effect. Among all the groups, SeC@PA(+) group showed the strongest anti-biofilm activity, which benefited from the generation of RNS and •OH. These results were consistent with the RS intensity results in the biofilm. Therefore, three types of RS generated by SeC@PA were involved in the anti-biofilm mechanism in this study, and this strategy is termed as “RS storm”. The anti-biofilm contributions of the three RS were quantified through crystal violet staining experiments (represented by the biomass of the biofilm). As shown in Supplementary Fig. 14, the contribution of 1O2, RNS and •OH against biofilm was 18.5%, 37.6%, and 30.2%, respectively.
The anti-biofilm efficacy of different treatments against single-species biofilms formed by SA and PA is shown in Fig. 3 and Supplementary Fig. 15. For typical live/dead biofilm images shown in Fig. 3a, Supplementary Figs. 10a, 16, and 17, the biofilms in the control group and C@PA group were relatively intact, and almost all viable bacteria were stained green. In comparison, the Se@PA and SeC@PA groups exhibited slight anti-biofilm activity due to the antibacterial activity of Se (Supplementary Fig. 18). In the C@PA(+) group, dead bacteria were stained red, and large-scale bacterial death was observed. Remarkably, the SeC@PA(+) group exhibited the lowest levels of viable bacteria, almost entirely covered by dead bacteria. Thus, the SeC@PA(+) group exhibited the best anti-biofilm effect among all groups. Figure 3c and Supplementary Fig. 15c depicted the colony-forming units (CFU) of SA and PA in agar plates, respectively. The quantification of CFUs for two types of single-species biofilm (Fig. 3e and Supplementary Fig. 15g) exhibited similar results for live/dead staining. The CFU values in the SeC@PA(+) group were reduced by 4, 3, and 1 orders of magnitude compared to control group, Se@PA group, and C@PA(+) group, respectively. Similarly, the lowest crystal violet absorbance value was detected in the SeC@PA(+) group for the crystal violet staining experiment (Fig. 3f and Supplementary Fig. 15e), indicating the lowest number of viable bacteria in this group.
To explore whether the SeC@PA(+) group could eradicate biofilms by decomposing GSH to generate higher levels of RS, the GSH concentration and RS in biofilms after different treatments were measured. The green fluorescent probe DCF-DA was used to evaluate RS generation in SA and PA biofilms. As shown in Fig. 3b, d, compared with the C@PA(+) group, the SeC@PA(+) group exhibited higher RS activity in SA biofilms. Whereas, in the group of biofilms incubated with Se@PA or SeC@PA without irradiation, the green fluorescence of RS was weak. These results suggested that SeC@PA(+) could promote RS generation in SA biofilms. Simultaneously, we measured the changes of GSH in the biofilms after treatments (Fig. 3g). As opposed to the groups without laser irradiation, the C@PA(+) and SeC@PA(+) groups could significantly reduce GSH levels in the biofilms by producing NO after laser irradiation, and GSH levels in SeC@PA(+) group was lower than that in the C@PA(+) group. These results were consistent with the findings obtained in in vitro experiments. Interestingly, the ability of SeC@PA(+) to eliminate GSH was significantly stronger than that of C@PA(+), indicating that Se was involved in the degradation of GSH after irradiation. Similar results were observed for PA biofilms (Supplementary Fig. 15b, d, f). The results indicated that GSH in the biofilm could be decomposed and scavenged by SeC@PA(+) to generate RS storm for biofilms eradication.
Antioxidant Properties of SeC@PA
RS produced by anti-biofilms further exacerbates the inflammatory response in wound beds. Therefore, the ideal therapeutic effect is that in the case of low levels of GSH, SeC@PA can not only scavenge the RS generated by the anti-biofilm but also eliminate RS generated by wound tissue. Human umbilical vein endothelial cells (HUVECs) were employed to validate the antioxidant properties of SeC@PA as HUVECs are extremely sensitive to RS. As illustrated in Fig. 4a, b, the SeC@PA(+) group demonstrated significantly lower levels of RS compared to the C@PA(+) group. Results from flow cytometry exhibited similar findings (Fig. 4c), indicating that SeC@PA could be an excellent RS scavenger. This behavior of SeC@PA was diametrically opposite to that in biofilms with high GSH levels. Glutathione peroxidase (GPX) is an important peroxidase widely presented in the body, and Se is a component of the GPX enzyme system31,32. To evaluate whether SeC@PA could promote the level and activity of GPX through biosynthesis and enhance the antioxidant capacity of wounds, we studied the level and activity of GPX4 after treatment. We labeled GPX4 in HUVECs with red fluorescence and observed them using laser confocal microscopy. As shown in Fig. 4d, the red fluorescence in the cytoplasm and nucleus was significantly enhanced in Se@PA and SeC@PA(+) treated groups compared to the control and C@PA(+) groups, suggesting an increase in GPX4 levels. We further analyzed GPX4 levels using western blotting, and the relative expression of GPX4 in the Se@PA and SeC@PA(+) groups was 1.64- and 1.79-fold higher than that in the control group, respectively (Fig. 4e, f). Subsequently, we examined GPX activity in different treatment groups. GPX activity in the SeC@PA(+) group was 1.74-fold higher than that in the control group, whereas GPX activity in the Se@PA group was 1.30-fold higher than that in the control group (Fig. 4g). Notably, application of C@PA(+) significantly reduced GPX activity compared to the control group, indicating that RS impaired GPX activity, which was reversed by SeC@PA.
Macrophage polarization–promoting properties of SeC@PA
Macrophages play a central role in regulating inflammation and promoting wound healing and undergo polarization into the M1- and M2-phenotypes33–35. Chronic wounds are infiltrated by M1-phenotype macrophages, resulting in a persistent inflammatory response that delays wound healing36,37. It has been proven that M2-phenotype macrophages play a key role in regulating inflammation, promoting angiogenesis, and wound healing38,39. Hence, enhancing macrophage polarization to the M2 phenotype provides an opportunity to accelerate chronic wound healing. We first used the characteristic surface biomarkers CCR7 and CD206 to identify M1- and M2-phenotype macrophages and determined the effects of different treatments on macrophage polarization40,41. After incubation with Se@PA and SeC@PA(+), a more pronounced green fluorescence of CD206 staining was observed compared with that in the other groups (Supplementary Fig. 19). Subsequently, flow cytometry was employed to determine the ratio of M1- and M2-phenotype macrophages by quantifying CCR7 and CD206 expression (Fig. 5a, Supplementary Figs. 20 and 21). After treatment with Se@PA and SeC@PA(+), the percentage of CD206+ M2-phenotype cells was significantly increased compared with that in the other groups, whereas the percentage of CCR7+ M1-phenotype cells were obviously decreased compared with treatment with C@PA(+).
Additionally, the expression of M2-phenotype macrophage marker genes, including CD206, interleukin (IL)-4, IL-10, and Arg-1, improved significantly after treatment with Se@PA and SeC@PA(+). In contrast, the M1-phenotype macrophage marker genes, including CD86, IL-1, inducible nitric oxide synthase (iNOS), and tumor necrosis factor (TNF)-α, were remarkably decreased in the Se@PA and SeC@PA(+) groups (Supplementary Fig. 22). The representative cytokine detection results of M2-like macrophages showed that IL-4 and IL-10 levels increased significantly and that IL-1 and TNF-α levels decreased considerably after SeC@PA(+) treatment (Fig. 5n–q). These results indicated that SeC@PA(+) could effectively activate macrophage polarization to the M2 phenotype.
To further explore the mechanism by which SeC@PA(+) promotes the polarization of macrophage to the M2-phenotype, we used quantitative real-time PCR (QPCR) and western blotting to elucidate the signaling pathway of SeC@PA(+). Previous studies have shown that Se levels can affect IL-4-promoted M2-macrophage polarization42. Therefore, we hypothesized that SeC@PA(+) could regulate the expression of certain signals in the IL-4 pathway and promote macrophages toward M2-type polarization. IL-4-mediated M2-macrophage polarization has been well established through a Janus kinase type 1 (JAK1) signal transducer and activator of the transcription 6 (STAT6) pathway43. We first investigated the expression of STAT6 mRNA after incubation with SeC@PA(+) and found a significant increase in its levels (Supplementary Fig. 23a). Notably, the mannose receptor (MR)-mediated polarization of macrophages toward the M2 type also increases STAT6 expression through the ERK-STAT6 pathway6. Therefore, we used western blotting to further confirm the mechanism of SeC@PA(+) in promoting macrophage polarization. The findings (Fig. 5b–e and Supplementary Fig. 24) showed that SeC@PA(+) significantly upregulated the levels of phosphorylated JAK (p-JAK1) and phosphorylated STAT6 (p-STAT6) but had no significant effect on phosphorylated ERK (p-ERK) levels, indicating that SeC@PA(+) activation occurred via the JAK-STAT6 pathway (Supplementary Fig. 23b).
Promotion of cell migration and angiogenesis by SeC@PA
The migration and tube formation in HUVECs cultured over SeC@PA(+) was evaluated (Fig. 5f–i and Supplementary Fig. 25). Unsurprisingly, cells in the C@PA(+) group were neither migrated nor angiogenesis was detected because RS production impairs the function of HUVECs. Conversely, after incubation with SeC@PA(+), cell migration and angiogenesis were restored due to the scavenging effect of RS. However, SeC@PA(+) treatment did not result in a significant increase in the migration and angiogenesis of HUVECs compared with those in the control group. Considering that the polarization of macrophages into the M2 type promotes wound healing, we further explored the influence of adding RAW264.7 cells on HUVECs behavior. Surprisingly, after adding RAW264.7 cells, SeC@PA(+) treatment significantly promoted the migration and tube-forming ability of HUVECs compared with those in the other groups. To determine whether this phenomenon was attributed to SeC@PA(+) stimulating RAW264.7 cells to secrete certain factors regulating the behavior of HUVECs, we determined the levels of vascular endothelial growth factor (VEGF) in cells after SeC@PA(+) treatment. As shown in Fig. 5j–m, the levels of VEGF in RAW264.7 cells were significantly increased compared with those in the control group. Conversely, the levels of VEGF in HUVECs treated with SeC@PA (+) group exhibited no obvious difference from those in the control group, indicating that SeC@PA(+) promoted RAW264.7 cells to secrete VEGF, thereby enhancing cell migration and tube-formation abilities of HUVECs. Overall, SeC@PA(+) could promote wound healing by regulating the polarization of macrophages to the M2 type, thereby secreting VEGF, which promotes migration and tube formation in HUVECs.
Treatment of non-biofilm-infected wounds in diabetic mice using SeC@PA bandage
Diabetic chronic wounds without infected biofilms were employed to verify the direct RS-scavenging effect of SeC@PA MN on wound tissues. The MN groups containing Se (Se@PA MN, Se@PA MN(+), SeC@PA MN, and SeC@PA MN(+) group) exhibited much higher wound healing rates compared to those without Se (Control, Control(+), C@PA MN, and C@PA MN(+) group), as demonstrated in Fig. 6a, f. This result could be attributed to the potent antioxidant capacity of Se. Conversely, the C@PA MN (+) group showed impaired wound healing due to aggravated oxidative stress caused by RS production, as shown in Fig. 6b, g. Interestingly, the level of RS in the SeC@PA MN (+) group was lower than that in the C@PA MN (+) group, suggesting a potential role for SeC@PA MN (+) in RS scavenging in wound tissues. Hematoxylin-eosin (HE) staining (Fig. 6c), Masson’s trichrome staining (Fig. 6d, h), and CD31 immunofluorescence (Fig. 6e, i) revealed that the Se-containing MN groups exhibited more regular skin structure, enhanced collagen deposition, and increased blood vessels density. Collectively, in the non-biofilm-infected diabetic chronic wound, Se-containing MN could reduce inflammation by scavenging RS, while promoting wound healing through collagen deposition and angiogenesis.
These results indicated that RS produced by PDT treatment alone (C@PA MN(+)) has the risk of delaying diabetic chronic wound healing. It is necessary to remove the RS produced by PDT immediately to avoid secondary injury to the wound tissues. SeC@PA MN (+) could effectively remove the RS produced by PDT in wound tissues, alleviate oxidative stress, and promote wound healing.
SeC@PA MN for promoting biofilm-infected chronic wound healing by efficient delivery of SeC@PA
Chronic diabetic wounds are mostly covered by inflammatory exudates and biofilms (Supplementary Fig. 26), forming physicochemical barriers that greatly reduce the bioavailability of topical drugs. To demonstrate the advantages of microneedle bandage in the treatment of diabetic chronic wounds, we compared the therapeutic effects of SeC@PA MN(+) with SeC@PA NPs(+). As shown in Fig. 7, the SeC@PA MN(+) group showed a strong impact in promoting wound healing (Fig. 7a, g) with higher collagen deposition fraction (Fig. 7c, h) and vessel density (Fig. 7d, i) relative to the control group and SeC@PA NPs(+) group. However, there was no obvious difference between the SeC@PA NPs(+) group and the control group in promoting wound healing.
To further explore whether the location of SeC@PA in the wound is responsible for the differences in therapeutic effects between SeC@PA MN(+) group and SeC@PA NPs(+) group, we investigated the distribution of SeC@PA after administration. Firstly, biofilms were generated by infecting chronic diabetic wounds with E. coli expressing GFP for easy observation. Secondly, SeR@PA MN and SeR@PA NPs were prepared by replacing Ce6 with rhodamine for better observation of the distribution of SeC@PA in the wound coverings. After two days of biofilm growth, SeR@PA MN and SeR@PA NPs were applied to the wound, respectively. As shown in Fig. 7e, f, SeR@PA MN effectively punctured the wound coverings and delivered SeR@PA to the underside of the wound coverings, and the penetration depth of SeR@PA was increased with the duration of administration. However, SeR@PA from SeR@PA NPs was mostly captured by the biofilms on the surface of the wound coverings, which could reach neither the biofilms deep in the wound coverings nor the area below it. To investigate the penetration efficiency of SeR@PA from SeR@PA MN and SeR@PA NPs into the wound coverings, the wound coverings were placed into transwells, which were then inserted into a 24-well plate to determine the amount of SeR@PA permeated into the well plates (Fig. 7j). The SeR@PA MN group showed higher wound covering penetration efficiency compared to that of SeR@PA NPs (Fig. 7k). At the same time, we performed bacterial coated plate counting on the wounds after 4 days of treatments with SeC@PA MN(+) and SeC@PA NPs(+), showing that the antibacterial effect of SeC@PA MN(+) was much stronger than that of SeC@PA NPs (+) group (Supplementary Fig. 27).
These results demonstrated the advantages exhibited by MNs in the field of treating chronic wounds. Chronic diabetic wounds are often covered with inflammatory exudates and biofilms, which form a physicochemical barrier that prevents the penetration of therapeutic drugs into the action sites beneath the wound coverings. Therefore, conventional local delivery methods have limitations in the treatment of chronic wounds. On the contrary, MNs can penetrate the physicochemical barrier on the wound surface to achieve deeper and wider drug delivery, effectively eradicating the biofilm, reducing oxidative stress, and promoting angiogenesis and collagen deposition in the wound to facilitate wound healing.
Treatment of biofilm-infected wounds in diabetic mice using SeC@PA MN bandage
Subsequently, we investigated the effects of SeC@PA MN on biofilm-infected diabetic chronic wounds. Firstly, we determined GSH content in wound coverings (including biofilms and inflammatory exudates) and wound tissues (beneath the wound coverings) to determine whether there were differences in GSH content to achieve the bidirectional regulatory effect of SeC@PA on RS. As displayed in Supplementary Fig. 28, the GSH content in the wound coverings was much higher than that in the wound tissue, with a content as high as 6.69 mmol/g, which was 9.3 times higher than 0.72 mmol/g in the tissue. This difference in GSH content could provide a basis for achieving different regulatory effects of SeC@PA on RS at the two sites.
SeC@PA MN significantly promoted wound healing after laser irradiation (Fig. 8 and Supplementary Fig. 29). After 16 days of treatment, wounds in the SeC@PA MN(+) group were almost healed with a healing rate >95%, whereas 22%, 16%, and 15% of the wound areas remained in the control group, C@PA MN(+) group, and Se@PA MN group, respectively (Fig. 8a, b, f). Hematoxylin-eosin (HE) staining (Fig. 8c) and Masson’s trichrome staining (Fig. 8d) were performed to investigate the histological changes of wounds treated with different treatment. On day 16, the control group showed only a few collagen deposits (Fig. 8g) and irregular skin structure, which was infiltrated by many inflammatory cells. Similar phenomena were found in the C@PA MN(+) and Se@PA MN groups. In the SeC@PA MN(+)-treated wounds, the epidermis and dermis of the skin were relatively intact and highly ordered, and inflammatory cell infiltration was less. Additionally, the relative CD31 fluorescence intensity (Fig. 8e, h and Supplementary Fig. 30) increased remarkably in SeC@PA MN(+)-treated wounds, suggesting a significantly higher density of vessels in the dermis from wounds cured by SeC@PA MN(+) compared with those in other groups.
Dihydroethidium staining was used to determine RS levels in wound tissues after different treatments on day 4. The experimental procedures are shown in Fig. 9a. The control group and C@PA MN(+) group displayed strong red fluorescence, indicating that the oxidative stress in wound tissue was severe (Fig. 9b,f and Supplementary Fig. 31). After the application of Se@PA MN and SeC@PA MN(+), RS levels decreased obviously, demonstrating that both MNs could scavenge RS. At the same time, we determined GPX4 level and activity in wound tissues (Fig. 9e, h, i) and found that SeC@PA MN could enhance both parameters. Unexpectedly, Se@PA MN did not obviously increase GPX4 activity and level in vivo, which was different from the results from in vitro studies. Moreover, the number of colonies in wound coverings after SeC@PA MN(+) treatment was much lower compared with other treatments (Fig. 9c, d, g), demonstrating the excellent anti-biofilm ability of SeC@PA MN(+) in vivo.
It is worth noting that the healing of chronic diabetic wounds is a complex process that requires simultaneous anti-biofilm and anti-inflammatory effects to promote healing. Se@PA MN can scavenge RS but cannot eradicate biofilms, exacerbating the inflammatory response in wounds. C@PA MN(+) can kill most bacteria by generating RS, which further aggravates the inflammatory response of wounds. Therefore, neither Se@PA MN nor C@PA MN(+) can effectively promote wound healing, which was consistent with the results of wound healing in our study. In addition, the detection of RS in Se@PA was limited to the early stage of wound healing (at day 4). Persistent bacterial infection aggravates the oxidative stress response in wounds and inactivates the functions of some enzymes such as GPX4, which may explain why Se@PA MN did not significantly increase GPX4 activity and levels. Therefore, SeC@PA MN(+) effectively promoted wound healing by eradicating biofilms and reducing inflammation, thereby increasing angiogenesis and collagen deposition.
Macrophage polarization by SeC@PA MN in vivo
An important indicator of the inflammatory response is the phenotype of macrophages44. It is well known that the infiltration of chronic wounds by M1-like macrophages results in a persistent inflammatory response that hinders wound healing. Therefore, modulation of macrophage polarization to the M2-phenotype with anti-inflammatory activity can benefit wound closure. To further illustrate the effect of SeC@PA MN(+) on macrophage polarization, the infiltration of macrophages into wounds was investigated using immunofluorescence staining. The wounds treated by SeC@PA MN(+) exhibited decreased M1-phenotype macrophage (F4/80+ and CD86+) infiltration and increased M2-phenotype macrophage (F4/80+ and CD206+) infiltration as compared with the control group and C@PA MN(+) group (Fig. 10a–d, Supplementary Fig. 32 and Supplementary Fig. 33). This result is attributed to Se promoting macrophage polarization to the M2-phenotype. In addition, SeC@PA MN(+) significantly increased the levels of the anti-inflammatory factors IL-4 and IL-10 and decreased those of the pro-inflammatory factors IL-1 and TNF-α, further demonstrating that macrophages were polarized to the M2- phenotype (Fig. 10e–h). Overall, SeC@PA MN(+) could promote the polarization of macrophages into an anti-inflammatory M2-phenotype and promote wound healing.
Discussion
Infected biofilms, persistent inflammation, and impaired angiogenesis are the hallmarks of diabetic chronic wounds. There is an urgent need to develop anti-biofilm, anti-inflammatory, and pro-angiogenic multifunctional agents to promote the healing of chronic diabetic wounds. PDT has been widely studied as antibacterial therapy owing to its virtue of generating ROS. However, high GSH concentrations in biofilms limit the therapeutic effect of PDT. In addition, ROS plays a dual role in eradicating biofilms and exacerbating inflammation. PDT produces a large amount of ROS in a short time. Although these ROS are transient, they can interfere with cell function, including that of HUVECs, and delay wound healing, especially in chronic wounds with severe oxidative stress, where this damage is more severe. Resolving this issue necessitates the introduction of additional ROS scavengers, which not only complicates the system but also impedes its clinical translation. Moreover, a frequently overlooked challenge lies in selecting the appropriate site of action, particularly in the context of chronic wound treatment. Chronic wounds are often covered with inflammatory exudates, which, together with biofilms, form barriers. Topically used drugs must pass through the barrier to reach the underlying live cells while combating the exudate transport occurring in the reverse direction, and therefore, the bioavailability of topical drugs is greatly reduced.
In this study, we design a single and highly effective SeC@ PA MN bandage to treat chronic diabetic wounds. As an emerging delivery system, MNs have been widely studied for their suitability in wound healing and other biological applications30,45–53. In our work, MN is used to puncture the physicochemical barrier covering the wound bed, leading to the subsequent delivery of cargo to the biofilms and active tissue. Compared with the local delivery SeC@PA NPs, the SeC@PA MN bandage can deliver SeC@PA directly to the biofilms and wound tissues below the wound coverings, greatly improving the bioavailability of the drug. When SeC@PA is delivered to biofilms with high GSH levels, •OH, which is more toxic than 1O2 (mainly produced by Ce6), is generated during irradiation through a series of cascade decomposition reactions. Simultaneously, NO, produced by LA, is employed to deplete GSH and generate RNS, forming an RS storm to eradicate the biofilm. This therapeutic effect cannot be achieved merely by depleting GSH to assist PDT. Both in vitro and in vivo studies demonstrate that the bacteria in the biofilms are efficiently eliminated by SeC@PA(+), indicating the effectiveness of the self-enhancing anti-biofilm strategy at high GSH levels. When applied to wound tissues with low GSH levels, SeC@PA acts as an RS scavenger, quickly quenches the RS produced by SeC@PA after irradiation, and increases the levels and activity of GPX4, thereby reducing wound inflammation. These results suggest that SeC@PA could dynamically regulate RS without extra additives by sensing different GSH levels, simultaneously eradicating biofilms and inhibiting inflammation.
Another obstacle in the healing process of chronic diabetic wounds is the infiltration of M1-phenotype macrophages. The anti-inflammatory effect due to the scavenging of ROS is transient. Remodeling the immune environment of the wound beds, especially polarizing macrophages to the M2-phenotype with a sustained anti-inflammatory effect, is necessary to promote healing. In this study, the SeC@PA clearly improves macrophage polarization into the M2-phenotype through the JAK-STAT6 pathways, promoting the levels of the anti-inflammatory factors IL-4 and IL-10 and reducing the levels of the pro-inflammatory factors. Macrophage polarization to the M2-phenotype promotes HUVEC migration and tube formation in vitro by secreting VEGF. The infiltration of M2-phenotype macrophages in wounds obviously increases in diabetic mice with chronic wounds, facilitating the inhibition of inflammation and promoting angiogenesis. Thus, this study represents the initial exploration of a potential therapeutic approach for chronic wounds by targeting the distinct microenvironments of biofilms and wound beds. These findings offer valuable insights into the rational design of topical treatments for the effective management of chronic wounds.
Methods
Preparation of Se-Ce6-DA-LA nanoparticles (SeC@PA)
Na2SeO3•5H2O (26.3 mg) was dissolved in ultrapure water (10 mL) containing 1% (v/v) tween 20. Next, vitamin C (70 mg) was dissolved in ultrapure water (10 mL). Na2SeO3 solution was added to vitamin C solution and stirred at room temperature for 10 h, and Se nanoparticles were collected by centrifugation. Subsequently, Se (1.5 mg) was suspended in ultrapure water (1 mL), followed by the addition of Ce6 (0.3 mg) and DA (10 mg) and adjustment of the pH with NaOH to 9.0. The mixture was stirred at room temperature for 24 h to obtain Se-Ce6-DA nanoparticles (SeC@P). Lastly, LA (50 mg) was added to SeC@P solution under stirring at room temperature for 12 h to obtain Se-Ce6-DA-LA nanoparticles (SeC@PA). The hydrodynamic size and zeta potential of Se, SeC@P, and SeC@PA were measured using a zeta potential analyzer (Malvern Mastersizer 2000, UK). The levels of Se, Ce6, and LA in SeC@PA were determined using inductively coupled plasma atomic emission spectrometry (PerkinElmer Optima8300, USA), ultraviolet spectrophotometry (Tecan/Infinite E plex, Switzerland), and the Sakaguchi reaction, respectively. The TEM (FEI Tecnai G2 F30, Netherlands) and scanning electron microscope (SEM, Regulus 8230, Japan) were employed to observe the appearance and detect the elemental composition of the SeC@PA, respectively.
The preparation of Ce6-DA-LA nanoparticles (C@PA) was similar to SeC@PA but without the addition of Se. The preparation of Se-DA-LA nanoparticles (Se@PA) was similar to SeC@PA but without the addition of Ce6.
Preparation of SeC@PA MN bandage
SeC@PA MNs were prepared using the centrifugal infusion polydimethylsiloxane (PDMS) mold method54,55. Briefly, SeC@PA was suspended in an aqueous solution containing 10% sucrose and 18% collagen, and then the solution (200 µL) was added to the PDMS mold using a pipette, followed by centrifugation (Centrifuge 5910R, Eppendorf, Shanghai, China) at 4600 × g and 4 °C for 3 min to fill the cavities. The residual suspension was removed with a pipette. Subsequently, the mold was centrifuged at 25 °C for 30 min to dry. Then, 18% aqueous polyvinyl alcohol (PVA) solution was added to the mold, centrifuged (Eppendorf) for 10 min (4600 × g, 4 °C), and stored in a desiccator overnight to obtain SeC@PA MNs. Se, Ce6, and LA levels in each MN patch were approximately 158.0 μg, 64.7 μg, and 97.1 μg, respectively. A biofilm was overlaid on an agarose gel to simulate the barriers of chronic wounds and the punctures of the barriers by the MNs were evaluated.
Detection of NO
NO levels were measured using a NO assay kit (Beyotime Biotechnology, Shanghai). Briefly, different concentrations of SeC@PA were exposed to a 660 nm laser (0.2 W/cm2) for different time periods, or SeC@PA was exposed to a 660 nm laser at different irradiation intensities. A NO standard curve was used to determine NO levels based on the absorbance of the sample at 550 nm.
Degradation of GSH in vitro
SeC@PA and C@PA were dispersed in GSH aqueous solution (8 mM). After exposure to a 660 nm laser for different time intervals, the GSH level remaining in the solution was determined using a microreduced GSH assay kit (Solarbio Science & Technology Co., Ltd., Beijing).
Extracellular measurement of RS
DCF-DA was used to determine the generation of total RS. Briefly, C@PA or SeC@PA (1 mg) was dispersed in PBS (1 mL, pH = 5.5) with or without GSH or with different concentrations of GSH. DCF-DA was added and irradiated using a 660 nm laser (0.2 W/cm2, 3 min). Subsequently, the fluorescence intensity was determined using an enzyme-linked immunosorbent assay (ELISA) analyzer (Tecan/Infinite E plex, Switzerland). EPR technique (EPR, Bruker EMXplus, Germany) was used to quantify the generation of •OH with DMPO. Different groups were treated with GSH, without GSH, or with different concentrations of GSH. Then, DMPO (60 μL) was added to determine •OH generation at room temperature with irradiation. MB was also used to quantify •OH generation. Thus, different groups were or were not treated with GSH. After irradiation for 3 min, the generation of •OH was determined by measuring the absorbance at 664 nm using a microplate reader.
Culturing PA and SA biofilms
Staphylococcus aureus (SA, ATCC 25923) and Pseudomonas aeruginosa (PA, ATCC 27853) were used in this study. For biofilm culturing, an SA suspension (10 μL, 108 CFU/mL) and Mueller-Hinton broth medium (MHB, 300 μL) were placed in 48-well plates and cultured at 37 °C for 2 d. The pH of the biofilm was adjusted by adding PBS (pH = 5.5) for in vitro experiments.
In vitro anti-biofilm effect of nanoparticles
The anti-biofilm effect of different nanoparticles was studied using live-dead staining, plate-counting assays, and crystal violet staining. For live-dead staining, different nanoparticles were incubated with the biofilms for 4 h and irradiated for 3 min. Two hours later, the treated biofilms were stained using a bacterial live-dead staining kit. Live and dead bacteria were observed using confocal laser microscopy (Zeiss LSM 880, Germany). For plate-counting assays, the treated biofilms were collected into PBS and dissolved by violent vortex. The number of bacteria was counted using the dilution-plate counting method. After treatment, 0.5% crystal violet solution was added to the biofilms, stained for 30 min, and washed 6 times with PBS. Lastly, the crystal violet was dissolved in methanol, and the absorbance at 590 nm was measured using a microplate reader. After treatment, the RS in biofilms was detected using DCF-DA and observed using fluorescence microscopy (ZEISS Axio Observer 3, Germany). GSH levels were determined using a micro-reduced GSH assay kit.
In vitro anti-inflammatory effect of nanoparticles
Different nanoparticles and HUVECs were incubated for 6 h and exposed to irradiation at 660 nm (0.2 W/cm2) for 3 min. RS production was determined using DCF-DA and observed using fluorescence microscopy (ZEISS Axio Observer 3, Germany). The generated RS was quantitatively analyzed using flow cytometry. Immunofluorescence staining of GPX4 was also performed. Western blot was used to determine GPX4 levels, and GPX activity was measured using a GSH peroxidase (GSH-Px/GPX) activity detection kit (Solarbio Science & Technology Co., Ltd, Beijing).
Macrophage polarization assessment in vitro
C@PA, Se@PA, SeC@PA, and RAW264.7 cells were incubated for 6 h and subsequently exposed to a 660 nm laser for 3 min. Total macrophages were labeled with rabbit F4/80 polyclonal primary antibody (M1 macrophages were labeled with rabbit CCR7 polyclonal primary antibody, and M2 macrophages were labeled with rabbit CD206 polyclonal primary antibody). The samples were subsequently analyzed using flow cytometry (Beckman cytoflex, Germany). qRT-PCR (ABI QuantStudio 5, USA) was used to determine the expression of specific genes in RAW264.7 macrophages after induction by nanoparticles (Supplementary Table 2). Western blotting was used to elucidate the mechanism of RAW264.7 cell polarization. The detailed procedure is provided in the Supplementary Information.
Assessment of cell migration and tube formation in vitro
After culturing HUVECs, scratches were created using a 200-μL pipette. C@PA and SeC@PA were added to cells and co-cultured for 6 h before laser irradiation for 3 min. For the group with RAW264.7, a transwell with a pore size of 0.4 μm coated with RAW264.7 cells was placed into the well plate containing HUVECs (Supplementary Fig. 25a). Wound healing was observed using fluorescence microscopy at 0 and 12 h after treatment. Tube formation was assessed using a six-well plate precoated with Matrigel matrix (BD, Corning, US) (Supplementary Fig. 25b). Western blotting was used to analyze the changes in VEGF in different treatment groups.
In vivo assessment of diabetic wound healing
Male BALB/c were purchased from the Laboratory Animal Center of Sun Yat-Sen University. All protocols for in vivo experiments were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University (SYSU-IACUC-2022-000945). All the mice (five mice per cage) were housed in standard, infection-free housing room, with 12 h light:12 h dark cycles in the vivarium. Diabetes was induced by a single intraperitoneal injection of 50 mg/kg streptozotocin (STZ, Sigma Aldrich) in citrate buffer (pH = 4.5) for consecutive 5 days. One week after STZ injection, the blood glucose levels of mice were continuously measured for 7 days, and those exhibiting levels >16.7 mM were considered diabetic56.
Subsequently, full-layer skin wounds were established in all diabetic mice (approximately 10 mm in diameter), which were coated with a bacterial mixture (100 μL) of SA and PA (108 CFU/mL). The chronic mouse model of diabetic wounds was considered to be successfully established when biofilms in wounds were formed after 2 days. The mice were randomly divided into the following four groups: control group, C@PA MN(+) group, Se@PA MN group, and SeC@PA MN(+) group. After 4, 8, 12, and 16 days, digital images of wounds were acquired and the wound area was calculated using ImageJ. The percentage of wound size was calculated as follows: [A(4,8,12,16)/A0] × 100%, where A0 and A(4,8,12,16) represent the wound areas on day 0 and days 4, 8, 12, and 16, respectively.
The pathological status and healing process of wounds were evaluated by H&E staining and Masson’s trichrome staining. Bacteria were characterized using Gram staining and counted using plate-counting assays. RS and CD31 expression were assessed using immunohistochemical staining and F4/80, CD86, and CD206 levels were determined using immunofluorescence staining.
Statistical analysis
The data here were presented as mean ± standard deviation. The statistical analyses were performed using GraphPad Prism 7.0 (La Jolla, CA, USA) software. Differences between two groups were analyzed by Student’s t test. Comparisons among the groups were performed using one-way ANOVA with Tukey’s multiple comparison test. In all cases, statistical significance was considered when p < 0.05.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Supplementary information
Source data
Acknowledgements
We are grateful for the financial support from the National Natural Science Foundation of China (32071342 and 32101065), the Science, Technology & Innovation Commission of Shenzhen Municipality (JCYJ20220818102810023), and the Singapore National Research Foundation under Its Competitive Research Program (NRF-CRP26-2021-0002).
Author contributions
X.W.Z, Y.L.Z and H.Z.C supervised the project. L.Y. designed the study and conceived the paper in discussions with X.W.Z., Y.L.Z. and H.Z.C. D.Z., W.J.L., C.D.D., L.L.W., Q.Y.L., H.B.L., Z.M.L. and L.M. contributed to the laboratory assistance. All authors read and approved the final manuscript.
Peer review
Peer review information
Nature Communications thanks Biao Dong, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
Data availability
All other data are available from the corresponding authors upon request. Source data are provided with this paper.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Hongzhong Chen, Email: chenhzh58@mail.sysu.edu.cn.
Yanli Zhao, Email: zhaoyanli@ntu.edu.sg.
Xiaowei Zeng, Email: zengxw23@mail.sysu.edu.cn.
Supplementary information
The online version contains supplementary material available at 10.1038/s41467-023-43067-8.
References
- 1.Hart T, Milner R, Cifu A. Management of a diabetic foot. JAMA. 2017;318:1387–1388. doi: 10.1001/jama.2017.11700. [DOI] [PubMed] [Google Scholar]
- 2.Chen H, et al. Dissolved oxygen from microalgae-gel patch promotes chronic wound healing in diabetes. Sci. Adv. 2020;6:eaba4311. doi: 10.1126/sciadv.aba4311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kim HS, et al. Advanced drug delivery systems and artificial skin grafts for skin wound healing. Adv. Drug Del. Rev. 2019;146:209–239. doi: 10.1016/j.addr.2018.12.014. [DOI] [PubMed] [Google Scholar]
- 4.Wang T, Li Y, Cornel EJ, Li C, Du J. Combined antioxidant-antibiotic treatment for effectively healing infected diabetic wounds based on polymer vesicles. ACS Nano. 2021;15:9027–9038. doi: 10.1021/acsnano.1c02102. [DOI] [PubMed] [Google Scholar]
- 5.Guan Y, et al. Sustained oxygenation accelerates diabetic wound healing by promoting epithelialization and angiogenesis and decreasing inflammation. Sci. Adv. 2021;7:eabj0153. doi: 10.1126/sciadv.abj0153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Liu W, et al. ECM-mimetic immunomodulatory hydrogel for methicillin-resistant Staphylococcus aureus-infected chronic skin wound healing. Sci. Adv. 2022;8:eabn7006. doi: 10.1126/sciadv.abn7006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Li G, et al. A small molecule HIF-1 alpha stabilizer that accelerates diabetic wound healing. Nat. Commun. 2021;12:3363. doi: 10.1038/s41467-021-23448-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Powers JG, Higham C, Broussard K, Phillips TJ. Wound healing and treating wounds: Chronic wound care and management. J. Am. Acad. Dermatol. 2016;74:607–625. doi: 10.1016/j.jaad.2015.08.070. [DOI] [PubMed] [Google Scholar]
- 9.Derakhshandeh H, et al. A wirelessly controlled smart bandage with 3D-printed miniaturized needle arrays. Adv. Funct. Mater. 2020;30:1905544. doi: 10.1002/adfm.201905544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Xiu W, et al. Potentiating hypoxic microenvironment for antibiotic activation by photodynamic therapy to combat bacterial biofilm infections. Nat. Commun. 2022;13:3875. doi: 10.1038/s41467-022-31479-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004;2:95–108. doi: 10.1038/nrmicro821. [DOI] [PubMed] [Google Scholar]
- 12.Hu D, Deng Y, Jia F, Jin Q, Ji J. Surface charge switchable supramolecular nanocarriers for nitric oxide synergistic photodynamic eradication of biofilms. ACS Nano. 2020;14:347–359. doi: 10.1021/acsnano.9b05493. [DOI] [PubMed] [Google Scholar]
- 13.Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat. Rev. Microbiol. 2017;15:740–755. doi: 10.1038/nrmicro.2017.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Xu QQ, et al. A biofilm microenvironment-activated single-atom iron nanozyme with NIR-controllable nanocatalytic activities for synergetic bacteria-infected wound therapy. Adv. Healthc. Mater. 2021;10:e2101374. doi: 10.1002/adhm.202101374. [DOI] [PubMed] [Google Scholar]
- 15.Xiu W, et al. Recent development of nanomedicine for the treatment of bacterial biofilm infections. View. 2021;2:20200065. doi: 10.1002/VIW.20200065. [DOI] [Google Scholar]
- 16.Xiu W, et al. Biofilm microenvironment-responsive nanotheranostics for dual-mode imaging and hypoxia-relief-enhanced photodynamic therapy of bacterial infections. Research. 2020;2020:9426453. doi: 10.34133/2020/9426453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Liu Y, Qin R, Zaat SAJ, Breukink E, Heger M. Antibacterial photodynamic therapy: overview of a promising approach to fight antibiotic-resistant bacterial infections. J. Clin. Transl. Res. 2015;1:140–167. [PMC free article] [PubMed] [Google Scholar]
- 18.Deng Y, et al. Nitric oxide as an all-rounder for enhanced photodynamic therapy: Hypoxia relief, glutathione depletion and reactive nitrogen species generation. Biomaterials. 2018;187:55–65. doi: 10.1016/j.biomaterials.2018.09.043. [DOI] [PubMed] [Google Scholar]
- 19.Kong, Q. et al. A novel Z-scheme heterostructured Bi2S3/Cu-TCPP nanocomposite with synergistically enhanced therapeutics against bacterial biofilm infections in periodontitis. Small19, e2302547 (2023). [DOI] [PubMed]
- 20.Carlisle AE, et al. Selenium detoxification is required for cancer-cell survival. Nat. Metab. 2020;2:603–611. doi: 10.1038/s42255-020-0224-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kim SJ, Choi MC, Park JM, Chung AS. Antitumor effects of selenium. Int. J. Mol. Sci. 2021;22:11844. doi: 10.3390/ijms222111844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Peng SY, et al. Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy. Biomaterials. 2022;281:121358. doi: 10.1016/j.biomaterials.2021.121358. [DOI] [PubMed] [Google Scholar]
- 23.Li J, et al. Transformation of arginine into zero-dimensional nanomaterial endows the material with antibacterial and osteoinductive activity. Sci. Adv. 2023;9:eadf8645. doi: 10.1126/sciadv.adf8645. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Sun Y, et al. A versatile nanocomposite based on nanoceria for antibacterial enhancement and protection from aPDT-aggravated inflammation via modulation of macrophage polarization. Biomaterials. 2021;268:120614. doi: 10.1016/j.biomaterials.2020.120614. [DOI] [PubMed] [Google Scholar]
- 25.Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–321. doi: 10.1038/nature07039. [DOI] [PubMed] [Google Scholar]
- 26.Liu T, et al. Selenium nanoparticles regulates selenoprotein to boost cytokine-induced killer cells-based cancer immunotherapy. Nano Today. 2020;35:100975. doi: 10.1016/j.nantod.2020.100975. [DOI] [Google Scholar]
- 27.Hu Y, et al. Selenium nanoparticles as new strategy to potentiate gamma delta T cell anti-tumor cytotoxicity through upregulation of tubulin-alpha acetylation. Biomaterials. 2019;222:119397. doi: 10.1016/j.biomaterials.2019.119397. [DOI] [PubMed] [Google Scholar]
- 28.Dai XM, et al. Simultaneous inhibition of planktonic and biofilm bacteria by self-adapting semiconducting polymer dots. J. Mater. Chem. B. 2021;9:6658–6667. doi: 10.1039/D1TB01070K. [DOI] [PubMed] [Google Scholar]
- 29.Flemming HC, et al. Biofilms: an emergent form of bacterial life. Nat. Rev. Microbiol. 2016;14:563–575. doi: 10.1038/nrmicro.2016.94. [DOI] [PubMed] [Google Scholar]
- 30.Woodhouse I, et al. Flexible microneedle array patch for chronic wound oxygenation and biofilm eradication. ACS Appl. Bio Mater. 2021;4:5405–5415. doi: 10.1021/acsabm.1c00087. [DOI] [PubMed] [Google Scholar]
- 31.Liu SD, et al. Regulation of artificial supramolecular transmembrane signal transduction by selenium-containing artificial enzyme receptors. Nano Res. 2023;16:946–969. [Google Scholar]
- 32.Zhuo P, et al. Molecular consequences of genetic variations in the glutathione peroxidase 1 selenoenzyme. Cancer Res. 2009;69:8183–8190. doi: 10.1158/0008-5472.CAN-09-1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Chen Q, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat. Nanotechnol. 2019;14:89–97. doi: 10.1038/s41565-018-0319-4. [DOI] [PubMed] [Google Scholar]
- 34.Kim B, et al. Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus. Nat. Commun. 2018;9:1969. doi: 10.1038/s41467-018-04390-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Knipper JA, Ding XL, Eming SA. Diabetes impedes the epigenetic switch of macrophages into repair mode. Immunity. 2019;51:199–201. doi: 10.1016/j.immuni.2019.07.009. [DOI] [PubMed] [Google Scholar]
- 36.Duan Y, et al. Unsaturated polyurethane films grafted with enantiomeric polylysine promotes macrophage polarization to a M2 phenotype through PI3K/Akt1/mTOR axis. Biomaterials. 2020;246:120012. doi: 10.1016/j.biomaterials.2020.120012. [DOI] [PubMed] [Google Scholar]
- 37.Li X, et al. Nanofiber-hydrogel composite-mediated angiogenesis for soft tissue reconstruction. Sci. Transl. Med. 2019;11:eaau6210. doi: 10.1126/scitranslmed.aau6210. [DOI] [PubMed] [Google Scholar]
- 38.Saleh B, et al. Local immunomodulation using an adhesive hydrogel loaded with miRNA-laden nanoparticles promotes wound healing. Small. 2019;15:e1902232. doi: 10.1002/smll.201902232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wu J, et al. Novel H2S-releasing hydrogel for wound repair via in situ polarization of M2 macrophages. Biomaterials. 2019;222:119398. doi: 10.1016/j.biomaterials.2019.119398. [DOI] [PubMed] [Google Scholar]
- 40.Ding C, et al. Macrophage-biomimetic porous Se@SiO2 nanocomposites for dual modal immunotherapy against inflammatory osteolysis. J. Nanobiotechnol. 2021;19:382. doi: 10.1186/s12951-021-01128-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Bellora F, et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc. Natl Acad. Sci. USA. 2010;107:21659–21664. doi: 10.1073/pnas.1007654108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Nelson SM, Lei X, Prabhu KS. Selenium levels affect the IL-4-induced expression of alternative activation markers in murine macrophages. J. Nutr. 2011;141:1754–1761. doi: 10.3945/jn.111.141176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604. doi: 10.1016/j.immuni.2010.05.007. [DOI] [PubMed] [Google Scholar]
- 44.Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44:450–462. doi: 10.1016/j.immuni.2016.02.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Yao S, et al. Porous MOF microneedle array patch with photothermal responsive nitric oxide delivery for wound healing. Adv. Sci. 2022;9:e2103449. doi: 10.1002/advs.202103449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Lei Q, et al. Microneedle patches integrated with biomineralized melanin nanoparticles for simultaneous skin tumor photothermal therapy and wound healing. Adv. Funct. Mater. 2022;32:2113269. doi: 10.1002/adfm.202113269. [DOI] [Google Scholar]
- 47.Su Y, et al. Simultaneous delivery of multiple antimicrobial agents by biphasic scaffolds for effective treatment of wound biofilms. Adv. Healthc. Mater. 2021;10:e2100135. doi: 10.1002/adhm.202100135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Xu J, et al. Microneedle patch-mediated treatment of bacterial biofilms. ACS Appl. Mater. Interfaces. 2019;11:14640–14646. doi: 10.1021/acsami.9b02578. [DOI] [PubMed] [Google Scholar]
- 49.Chen W, et al. Reducing false negatives in COVID-19 testing by using microneedle-based oropharyngeal swabs. Matter. 2020;3:1589–1600. doi: 10.1016/j.matt.2020.09.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Zhang XX, et al. Immunomodulatory microneedle patch for periodontal tissue regeneration. Matter. 2022;5:666–682. doi: 10.1016/j.matt.2021.11.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Yang L, Yang Y, Chen HZ, Mei L, Zeng XW. Polymeric microneedle-mediated sustained release systems: design strategies and promising applications for drug delivery. Asian J. Pharm. Sci. 2022;17:70–86. doi: 10.1016/j.ajps.2021.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Wang L, et al. A microneedle-based delivery system for broad-protection seasonal influenza A DNA nanovaccines. Cell Rep. Phys. Sci. 2023;4:101430. doi: 10.1016/j.xcrp.2023.101430. [DOI] [Google Scholar]
- 53.Yang L, et al. Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency. Acta Pharm. Sin. B. 2023;13:344–358. doi: 10.1016/j.apsb.2022.04.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sun Y, et al. Self-assembly nanomicelle-microneedle patches with enhanced tumor penetration for superior chemo-photothermal therapy. Nano Res. 2022;15:2335–2346. doi: 10.1007/s12274-021-3817-x. [DOI] [Google Scholar]
- 55.Lin SQ, et al. Strategy for hypertrophic scar therapy: improved delivery of triamcinolone acetonide using mechanically robust tip-concentrated dissolving microneedle array. J. Control. Release. 2019;306:69–82. doi: 10.1016/j.jconrel.2019.05.038. [DOI] [PubMed] [Google Scholar]
- 56.Ouyang J, et al. In situ sprayed NIR-responsive, analgesic black phosphorus-based gel for diabetic ulcer treatment. Proc. Natl Acad. Sci. USA. 2020;117:28667–28677. doi: 10.1073/pnas.2016268117. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All other data are available from the corresponding authors upon request. Source data are provided with this paper.